Text Size

Glaucoma Research Foundation to Host 4th Annual Glaucoma 360 New Horizons Forum

San Francisco, CA - January 16, 2015: Glaucoma Research Foundation will host the fourth annual Glaucoma 360 New Horizons Forum on February 6, 2015 at the historic Palace Hotel in San Francisco. The singular goal of this endeavor is to speed the development of new, more effective therapies and diagnostics for glaucoma patients.


Glaucoma 360 was founded by Adrienne Graves, PhD, and Andrew G. Iwach, MD, both of whom serve on the Glaucoma Research Foundation Board of Directors. Drs. Graves and Iwach also serve as Co-Chairs for Glaucoma 360.

Dr. Graves explains, “Innovators may need guidance to advance their ideas, early-stage companies may need additional financing to proceed with product development, and venture capitalists and industry executives are looking for the next opportunities. The New Horizons Forum gathers everyone together to stimulate and facilitate key discussions and connections. Showcasing the latest innovations, in a diverse audience of clinicians/VCs/industry/FDA, is a way for GRF to serve as a catalyst in the development of new glaucoma products.”

Dr. Iwach, Glaucoma Research Foundation’s Board Chair and Executive Director at the Glaucoma Center of San Francisco, added “From a physician standpoint, we need better solutions to help patients. This meeting fosters collaboration and partnership and our goal is to accelerate the development of new treatments and potentially a cure.” Iwach added, “This is the only innovation meeting of its kind dedicated solely to glaucoma, and once again we have an outstanding line-up of speakers and presenting companies.”


Paul P. Lee, MD, JD, the F. Bruce Fralick Professor and chair of the Department of Ophthalmology and Visual Sciences at the University of Michigan Kellogg Eye Center will deliver the Drs. Henry and Frederick Sutro Memorial Lecture, the keynote lecture to start the full day of presentations and industry panel discussions featuring new innovations in glaucoma drug delivery, pharmaceuticals, and devices, as well as sessions focusing on working with the FDA and securing venture capital funding.

Attendees and speakers include nationally and internationally respected leaders in medicine, science, business, venture capital, and the FDA.

Speakers, panelists and discussion leaders include Stuart B. Abelson, MBA, President and CEO, Ora, Inc. (Andover, MA); Paul Chaney, President and CEO, PanOptica, Inc. (Bernardsville, NJ); Ernie Bravo, Global Marketing Director, Surgical Glaucoma, Alcon Laboratories, Inc. (Fort Worth, TX); Ernest Cavin, PhD, President, Haag-Streit (Mason, OH); Wiley Chambers, MD, Supervisory Medical Officer, Division of Transplant & Ophthalmology, Federal Drug Administration (FDA); Paul Chaney, President and CEO, PanOptica, Inc. (Bernardsville, NJ); George A. Cioffi, MD, Chairman, Department of Ophthalmology, Columbia University College of Physicians and Surgeons (New York, NY); Alan S. Crandall, MD, Sr. Vice Chairman of Ophthalmology and Visual Sciences, John A. Moran Eye Center, University of Utah (Salt Lake City, UT); Eugene de Juan, Jr., MD, Founder and Vice-Chairman, ForSight Labs (Menlo Park, CA); Malvina Eydelman, MD, Director, Division of Ophthalmic Device Evaluation, Federal Drug Administration (FDA); Robert Fechtner, MD, Director, Glaucoma Division, Department of Ophthalmology and Visual Sciences, Rutgers New Jersey Medical School (Newark, NJ); Doug Hubatsch, Senior Global Brand Lead, Medical Affairs, Alcon Laboratories, Inc. (Fort Worth, TX); Gil Kliman, MD, Managing Director, InterWest Partners (Menlo Park, CA); Ralf Kuschnereit, President and CEO, Carl Zeiss Meditec (Dublin, CA); Eliot Lazar, MD, President, elCON Enterprises, Inc. (Buffalo, NY); Richard Lindstrom, MD, Founder, Minnesota Eye Consultants, PA (Minneapolis, MN); K. Angela MacFarlane, JD, President and CEO, ForSight Labs (Menlo Park, CA); Ed Mathers, Partner, New Enterprise Associates (Menlo Park, CA); Cynthia Mattox, MD, FACS, Director, Glaucoma and Cataract Service, New England Eye Center, Associate Professor and Vice Chair, Department of Ophthalmology, Tufts University School of Medicine (Boston, MA); J. Casey McGlynn, JD, Partner, Wilson Sonsini Goodrich & Rosati (Palo Alto, CA); Eydie Miller-Ellis, MD, Professor of Clinical Ophthalmology, Director, Glaucoma Services, Scheie Eye Institute (Philadelphia, PA); Gary D. Novack, PhD, President, Pharmalogic Development, Inc., Visiting Professor of Pharmacology and Ophthalmology, University of California Davis, School of Medicine (San Rafael, CA); David Parke, II, MD, Executive Vice President and CEO, American Academy of Ophthalmology (San Francisco, CA); Jane Rady, Divisional Vice President, Abbott Medical Optics, Inc.(Santa Ana, CA); Thomas W. Samuelson, MD, Founding Partner, Minnesota Eye Consultants, Adjunct Associate Professor of Ophthalmology, University of Minnesota (Minneapolis, MN); Joel Schuman, MD, FACS, Chairman, Department of Ophthalmology, University of Pittsburgh (Pittsburgh, PA); Kuldev Singh, MD, MPH, Professor of Ophthalmology, Stanford University Medical Center (Stanford, CA); George L. Spaeth, MD, Louis J. Esposito Research Professor, Wills Eye Hospital (Philadelphia, PA); Tracy Valorie, BS, MBA Vice President and General Manager, Bausch + Lomb Pharmaceuticals (Rochester, NY); Rohit Varma, MD, MPH, Chair, Department of Ophthalmology, Director, USC Eye Institute, Associate Dean, Keck School of Medicine, USC (Los Angeles, CA) Steven Vold, MD, Founder & CEO, Vold Vision, PLLC (Fayetteville, AR); Robert N. Weinreb, MD, Chairman and Distinguished Professor of Ophthalmology, Director, Shiley Eye Center, University of California, San Diego (San Diego, CA); and Ruth Williams, MD, President, Wheaton Eye Clinic (Wheaton, IL)

Presenting companies featured include Aerie Pharmaceuticals, Inc.; AqueSys, Inc.; Bausch + Lomb; ClearSide Biomedical, Inc.; DSM Biomedical; Envisia Therapeutics; Euclid Systems; EyeSonic LLC; EyeTechCare; ForSight VISION5; Glaukos Corporation; GrayBug; Implandata Opthalmic Products GmbH; InnFocus, Inc.; iSTAR Medical; Ivantis; Mati Therapeutics; New World Medical; Ocular Therapeutix, Inc.; Ohr; Replenish; Sensimed; SOLX; and Transcend Medical.

The New Horizons Forum is the centerpiece of Glaucoma 360, Glaucoma Research Foundation’s signature three-day event which includes a fundraising Gala honoring Adrienne L. Graves, PhD, 2012 Nobel Laureate Shinya Yamanaka, MD, PhD and Masayo Takahashi, MD, PhD, as well as a continuing medical education program for clinicians. All proceeds from Glaucoma 360 support Glaucoma Research Foundation’s research and education programs. To learn more about the February 5-7, 2014 event at San Francisco’s historic Palace Hotel, and to register, visit: www.glaucoma360.org.

About Glaucoma Research Foundation

Founded in 1978 and headquartered in San Francisco, Glaucoma Research Foundation is America's oldest and most experienced nonprofit dedicated solely to its mission: to prevent vision loss from glaucoma by investing in innovative research, education and support with the ultimate goal of finding a cure. Glaucoma Research Foundation has invested more than $50 million into research and education to prevent vision loss from glaucoma. More information is available on the glaucoma.org website. Contact: Andrew Jackson, Director of Communications, phone (415) 986-3162.

Last reviewed on October 29, 2017

Was this helpful? Yes No